Study guide
Biotherapy, Immunotherapy, and Immune-Related Adverse Events
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Biotherapy, Immunotherapy, and Immune-Related Adverse Events
Key Takeaways Explain This Topic AI
Checkpoint inhibitors release immune brakes (PD-1, PD-L1, CTLA-4) and can inflame almost any organ as immune-related adverse events (irAEs).
irAEs follow CTCAE grading; Grade 1 often continues with monitoring, Grade 2 usually holds therapy, Grade 3 generally means hold plus high-dose corticosteroids (some, such as pneumonitis, mean permanent discontinuation), and Grade 4 generally means permanent discontinuation.
Pneumonitis, colitis, hepatitis, myocarditis, and hypophysitis are the high-mortality irAEs requiring same-day escalation.
irAEs can appear weeks to months after starting therapy and even after the last dose, so delayed-onset teaching is essential.
Patients should report new diarrhea, cough, jaundice, or fatigue before self-treating with antidiarrheals or steroids.
Last updated: October 2026
Biotherapy, Immunotherapy, and Immune-Related Adverse Events
Biotherapy uses biological agents (monoclonal antibodies, cytokines, vaccines, engineered immune cells) to treat cancer; immunotherapy is the dominant subgroup. Unlike cytotoxic chemotherapy, these agents often spare hair and marrow but cause inflammatory and immune emergencies. On the OCN exam this maps to both Treatment Modalities and Oncologic Emergencies items.
How Checkpoint Inhibitors Work
Immune checkpoint inhibitors (ICIs) release the brakes on T cells. Programmed cell death protein 1 (PD-1) inhibitors (nivolumab, pembrolizumab) and PD-ligand 1 (PD-L1) inhibitors (atezolizumab, durvalumab) restore T-cell recognition; cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (ipilimumab) act earlier in priming and cause more frequent, more severe toxicity, especially in combination. The same mechanism breaks immune tolerance in normal tissue, producing immune-related adverse events (irAEs) .
irAEs by Organ System
- Organ system Hallmark symptoms
- Lung (pneumonitis) New cough, dyspnea, hypoxia, chest tightness
- Bowel (colitis) Watery diarrhea, cramping, blood or mucus in stool
- Liver (hepatitis) Jaundice, dark urine, right-upper-quadrant pain, rising transaminases
- Endocrine (thyroiditis, hypophysitis) Fatigue, headache, hypotension, heat/cold intolerance, glucose change
- Heart (myocarditis) Chest pain, dyspnea, arrhythmia, troponin rise (rare but high-mortality)
- Skin Diffuse rash, pruritus, blistering, mucosal sores
- CTCAE Grading Drives Management
Management follows the Common Terminology Criteria for Adverse Events (CTCAE) and society guidelines. A practical framework:
Grade 1 (mild): usually continue therapy with closer monitoring.
Grade 2 (moderate): usually hold the ICI and start corticosteroids such as prednisone 0.5-1 mg/kg/day.
Grade 3-4 (severe/life-threatening): hold therapy, admit, give high-dose corticosteroids about 1-2 mg/kg/day, and add immunosuppressants (infliximab for steroid-refractory colitis) per protocol. Some grade 3 reactions, such as pneumonitis, mean permanent discontinuation, and Grade 4 (life-threatening) reactions generally mean permanent discontinuation; immune-mediated endocrinopathies are the usual exception: withhold until clinically stable or permanently discontinue depending on severity, with hormone replacement as indicated.
The RN supports grading using approved tools but does not independently grade, hold, restart, or prescribe steroids.
RN Assessment at Every Visit
Patients on immunotherapy may minimize symptoms because they feel hopeful about a new drug, so the nurse asks targeted, organ-by-organ questions rather than a generic side-effect screen. Compare bowel pattern with baseline (number and consistency of stools), review respiratory status and any new oxygen need, ask about headache and vision changes that can signal hypophysitis, quantify fatigue, and screen for new muscle weakness, chest pain, palpitations, confusion, or decreased urine output.
Laboratory monitoring commonly includes liver tests, kidney function, complete blood count, thyroid-stimulating hormone with free thyroxine, glucose, and cortisol when an endocrinopathy is suspected. The RN reports trends and clinically important changes early rather than waiting for severe symptoms, because a Grade 1 finding caught early may avoid a Grade 3 admission.
Infusion and Cytokine Risks
Some biologic agents also cause acute infusion reactions or cytokine release with fever, chills, hypotension, hypoxia, or rigors; rituximab and other CD20 antibodies are classic examples and often use premedication and a graded infusion rate. Monitoring matches the agent's risk profile and policy, including extended observation when required, and escalation is rapid for respiratory compromise, hypotension, altered mental status, chest pain, or persistent high fever.
Delayed Onset and Patient Education
irAEs are not infusion allergies. Rash and diarrhea may appear within weeks, endocrinopathies evolve over months, and toxicity can surface after the last dose . Teach patients to call for persistent diarrhea, new cough or dyspnea, yellow skin or eyes, severe headache, confusion, chest pain, palpitations, or severe rash, and to avoid self-treating significant diarrhea with antidiarrheals before calling, because masking colitis delays steroid therapy. Common misattributions trip patients up: diarrhea is blamed on food poisoning, cough on seasonal allergies, fatigue on aging.
Wallet or treatment cards help emergency clinicians who may misread an irAE as routine infection and prescribe antibiotics instead of corticosteroids. Because infection, embolism, progression, and irAEs overlap, prompt oncology involvement and clear handoffs are essential to prevent fragmented care and delayed treatment of serious organ inflammation.
The High-Mortality irAEs
Not all irAEs carry equal risk, and the exam emphasizes the lethal ones. Pneumonitis can progress from a dry cough to respiratory failure within days and is a leading cause of ICI-related death; any new or worsening dyspnea or hypoxia is treated as pneumonitis until imaging excludes it. Colitis can perforate, so high-volume or bloody diarrhea is urgent. Myocarditis is rare but carries the highest case-fatality rate of any irAE; chest pain, dyspnea, palpitations, or a troponin rise demands immediate cardiology involvement.
Hypophysitis (pituitary inflammation, most associated with CTLA-4 agents) presents insidiously with fatigue, headache, and hypotension and can precipitate adrenal crisis; it usually requires lifelong hormone replacement even after the drug stops. Diabetic ketoacidosis from autoimmune insulin deficiency and severe cutaneous reactions such as Stevens-Johnson syndrome round out the emergencies. A practical teaching anchor for patients and nurses alike: with immunotherapy, almost any new inflammation anywhere in the body could be the drug, so report early and let the team grade it rather than self-treating or waiting.
The corticosteroid course used to treat a serious irAE is usually tapered slowly over several weeks, and patients on prolonged steroids need opportunistic-infection prophylaxis, glucose monitoring, and bone protection, so the nurse reinforces not stopping steroids abruptly and watching for steroid side effects alongside the original toxicity.